ArticleJournal of applied toxicology : JAT2026
PM2.5 Exacerbates Viral Myocarditis by Disrupting Lysophosphatidylcholine Metabolism and Inhibiting the GPR4/ERK/PPARγ Pathway.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epidemiological studies link fine particulate matter (PM2.5) exposure to aggravated viral myocarditis (VMC), though the mechanisms remain unclear. This study aimed to investigate whether PM2.5 exacerbates the inflammatory response by disrupting lysophosphatidylcholine (LPC) metabolism and its downstream signaling pathways. We established the mouse model combining PM2.5 exposure and CVB3 infection. Cardiac function, inflammation, and signaling molecule alterations were assessed using echocardiography, histological analysis, and molecular techniques. In H9c2 cardiomyocytes, we applied PM2.5, LPC, GPR4 siRNA, and pathway inhibitors (U0126 and GW9662). PM2.5 reduced LPC levels in vivo and in vitro and downregulated its receptor GPR4. It also suppressed the ERK/PPARγ pathway, thereby lifting transcriptional inhibition of Toll-like receptor 4 (TLR4). GPR4 knockdown abolished the activating effects of LPC on ERK/PPARγ and its inhibitory effect on TLR4. Our study also confirmed that ERK and PPARγ function sequentially downstream of GPR4 and upstream of TLR4 within this pathway. The study suggests a novel mechanism by which PM2.5 exacerbates VMC. PM2.5 disrupts LPC metabolism, inhibits the GPR4/ERK/PPARγ pathway, and consequently releases the inhibition on TLR4, thereby increasing cardiac susceptibility to CVB3 and inflammatory injury. This pathway represents a potential therapeutic target for preventing PM2.5-associated myocardial damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.